Short Interest in Kamada Ltd. (NASDAQ:KMDA) Increases By 112.9%

Kamada Ltd. (NASDAQ:KMDA) was the recipient of a large increase in short interest in the month of February. As of February 13th, there was short interest totaling 166,435 shares, an increase of 112.9% from the January 29th total of 78,160 shares. Approximately 0.5% of the company’s stock are sold short. Based on an average trading volume of 69,886 shares, the days-to-cover ratio is presently 2.4 days. Based on an average trading volume of 69,886 shares, the days-to-cover ratio is presently 2.4 days. Approximately 0.5% of the company’s stock are sold short.

Institutional Investors Weigh In On Kamada

Several institutional investors have recently bought and sold shares of KMDA. Jane Street Group LLC acquired a new stake in Kamada during the first quarter valued at $582,000. Goldman Sachs Group Inc. acquired a new stake in shares of Kamada during the 1st quarter valued at about $497,000. Essex Investment Management Co. LLC lifted its holdings in shares of Kamada by 22.4% during the 3rd quarter. Essex Investment Management Co. LLC now owns 396,434 shares of the biotechnology company’s stock valued at $2,751,000 after buying an additional 72,602 shares during the last quarter. Arrowstreet Capital Limited Partnership bought a new stake in shares of Kamada in the 2nd quarter valued at approximately $472,000. Finally, Bank of America Corp DE increased its holdings in Kamada by 201.0% in the third quarter. Bank of America Corp DE now owns 61,565 shares of the biotechnology company’s stock worth $427,000 after buying an additional 41,111 shares during the last quarter. Institutional investors and hedge funds own 20.38% of the company’s stock.

Kamada Price Performance

NASDAQ:KMDA traded down $0.21 during midday trading on Friday, reaching $8.70. 52,124 shares of the company traded hands, compared to its average volume of 69,531. The firm has a market capitalization of $500.34 million, a price-to-earnings ratio of 24.17, a price-to-earnings-growth ratio of 0.76 and a beta of 0.94. The company has a fifty day moving average price of $8.08 and a 200 day moving average price of $7.34. Kamada has a twelve month low of $5.54 and a twelve month high of $9.35.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Benchmark reaffirmed a “buy” rating on shares of Kamada in a research report on Thursday, January 8th. Wall Street Zen raised shares of Kamada from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 13th. Weiss Ratings reissued a “buy (b-)” rating on shares of Kamada in a report on Thursday, January 22nd. Finally, HC Wainwright upped their target price on shares of Kamada from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.00.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.